Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 4/20 | 0.77 |
| ▸ | KDR | P35968 | 5/20 | 0.61 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.61 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.61 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.61 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.61 |
| ▸ | PRKACA | P17612 | 3/20 | 0.61 |
| ▸ | CDK8 | P49336 | 3/20 | 0.61 |
| ▸ | JAK2 | O60674 | 2/20 | 0.61 |
| ▸ | RET | P07949 | 2/20 | 0.61 |
| ▸ | GSK3A | P49840 | 2/20 | 0.61 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.61 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.61 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.61 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.61 |
| ▸ | CSF1R | P07333 | 2/20 | 0.61 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.61 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.61 |
| ▸ | AURKA | O14965 | 1/20 | 0.61 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21643997 | 0.87 | DYRK1A (1.00) | DYRK1AKDRCLK4MAP2K1DYRK1B | |
| SCHEMBL10850315 | 0.84 | DYRK1A (0.66) | DYRK1AKDRCLK4MAP2K1DYRK1B | |
| SCHEMBL3514678 | 0.84 | DYRK1A (0.70) | DYRK1AKDRCLK4MAP2K1DYRK1B | |
| Hydrochloric Acid SCHEMBL21411936 | 0.82 | DYRK1A (0.68) | DYRK1AKDRCLK4MAP2K1DYRK1B | |
| SCHEMBL23535573 | 0.82 | MAP4K4 (0.63) | DYRK1AKDRCLK4MAP2K1DYRK1B | |
| SCHEMBL23535604 | 0.82 | CLK4 (0.63) | DYRK1AKDRCLK4MAP2K1DYRK1B | |
| SCHEMBL31265360 | 0.82 | MAP4K4 (0.63) | DYRK1AKDRCLK4MAP2K1DYRK1B | |
| SCHEMBL3515178 | 0.81 | DYRK1A (0.66) | DYRK1AKDRCLK4MAP2K1DYRK1B | |
| SCHEMBL21076234 | 0.80 | DYRK1A (0.60) | DYRK1AKDRCLK4MAP2K1DYRK1B | |
| SCHEMBL12970527 | 0.80 | DYRK1A (0.64) | DYRK1AKDRCLK4MAP2K1DYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2022-11-08 | — | — | US | disclosed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| CN-112472699-A | Combination methods for improving the therapeutic benefit of bisantrene and derivatives | 种族肿瘤学公司 | 2021-03-12 | — | — | CN | disclosed |
| US-10927075-B2 | Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease | THE JACKSON LABORATORY (US) | 2021-02-23 | — | — | US | disclosed |
| EP-3229793-B1 | COMPOSITIONS AND METHODS RELATING TO THE TREATMENT OF CANCER, AUTOIMMUNE DISEASE, AND NEURODEGENERATIVE DISEASE | JACKSON LAB (US) | 2020-11-04 | — | — | EP | disclosed |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | SG CREDIT PARTNERS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-8324211-B2 | 6-Dimethylamino-2-(2-hydroxymethyl-3-{8-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-imidazo[1,2-b]pyridazin-6-yl }-phenyl)-3,4-dihydro-2H-isoquinolin-1-one; asthma, lupus ; inhibit Btk | ROCHE PALO ALTO LLC (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324211-B2 | 6-Dimethylamino-2-(2-hydroxymethyl-3-{8-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-imidazo[1,2-b]pyridazin-6-yl }-phenyl)-3,4-dihydro-2H-isoquinolin-1-one; asthma, lupus ; inhibit Btk | ROCHE PALO ALTO LLC (US) | 2012-12-04 | — | — | US | disclosed |
| WO-2012007416-A1 | BICYCLIC PYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-19 | — | — | WO | disclosed |
| CN-102066370-A | Novel phenyl-imidazopyridines and pyridazines | HOFFMANN LA ROCHE | 2011-05-18 | — | — | CN | disclosed |
| EP-2307413-A1 | NOVEL PHENYL-IMIDAZOPYRIDINES AND PYRIDAZINES | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| EP-2307413-A1 | NOVEL PHENYL-IMIDAZOPYRIDINES AND PYRIDAZINES | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010006947-A1 | NOVEL PHENYL-IMIDAZOPYRIDINES AND PYRIDAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010006947-A1 | NOVEL PHENYL-IMIDAZOPYRIDINES AND PYRIDAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016301-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2010-01-21 | — | — | US | disclosed |
| US-20100016301-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | DYRK1A 4018/4885KDR 3803/4885CLK4 4716/4885 |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | DYRK1A 4018/4885KDR 3803/4885CLK4 4716/4885 |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | DYRK1A 4018/4885KDR 3803/4885CLK4 4716/4885 |
| US-10927075-B2 | Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease | OGG1, MGMT, TDP1 | DYRK1A 3846/4885KDR 4790/4885CLK4 4554/4885 |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | DYRK1A 2828/4885KDR 2608/4885CLK4 3625/4885 |
| US-20100016301-A1 | Inhibitors of bruton's tyrosine kinase | BTK, SYK, LYN | DYRK1A 95/4885KDR 812/4885CLK4 1371/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | DYRK1A 4018/4885KDR 3803/4885CLK4 4716/4885 |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | DYRK1A 4055/4885KDR 3420/4885CLK4 4632/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | DYRK1A 2828/4885KDR 2608/4885CLK4 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.